Objective-Angiotensin-II (Ang-II) promotes the interaction of mononuclear cells with arterioles and neutrophils with postcapillary venules. To investigate the mechanisms underlying this dissimilar response, the involvement of fractalkine (CX 3 CL1) was explored. Methods and Results-Enhanced CX 3 CL1 expression was detected in both cremasteric arterioles and postcapillary venules 24 hours after Ang-II intrascrotal injection. Arteriolar leukocyte adhesion was the unique parameter significantly reduced (83%) in animals lacking CX 3 CL1 receptor (CX 3 CR1). Human umbilical arterial and venous endothelial cell stimulation with 1 μmol/L Ang-II increased CX 3 CL1 expression, yet neutralization of CX 3 CL1 activity only significantly inhibited Ang-II-induced mononuclear cell-human umbilical arterial endothelial cell interactions (73%) but not with human umbilical venous endothelial cells. The use of small interfering RNA revealed the involvement of tumor necrosis factor-α in Ang-II-induced CX 3 CL1 upregulation and mononuclear cell arrest. Nox5 knockdown with small interfering RNA or pharmacological inhibition of extracellular signal-regulated kinases1/2, p38 mitogen-activated protein kinase, and nuclear factor-κB also abolished these responses. Finally, when human umbilical arterial endothelial cells were costimulated with Ang-II, tumor necrosis factor-α, and interferon-γ, CX 3 CL1 expression and mononuclear cell adhesiveness were more pronounced than when each stimulus was provided alone. 
I
n cardiovascular diseases, such as hypertension, obesity and diabetes mellitus, increases in the levels of several circulating mediators, including angiotensin-II (Ang-II) or cytokines, have deleterious effects on endothelial function. 1, 2 These agents initiate an inflammatory signal cascade associated with reactive oxygen species (ROS) generation, increased cellsurface expression of cell adhesion molecules (CAMs), and enhanced leukocyte adhesiveness to endothelial cells. 1, 3 These responses are associated with endothelial dysfunction, which contributes to the early stages of the atherogenic process. [3] [4] [5] Ang-II is implicated in atherogenesis, 6 and we have previously demonstrated that 4-hour exposure to Ang-II in vivo causes arteriolar leukocyte adhesion in the mesenteric microcirculation of the rat. 7 Notably, although mononuclear cells were found to be the main type of cell attached to the arteriolar endothelium, the leukocytes interacting with the venular endothelium were predominantly neutrophils. Because the same CAMs were expressed on both the arteriolar and venular endothelia in response to Ang-II, 7 other mechanisms seem to be responsible for the differential cellular distribution within the microcirculation. Indeed, arteriolar mononuclear leukocyte recruitment by Ang-II was found to be largely mediated by tumor necrosis factor-α (TNFα). 8 In addition to CAMs, chemoattractant molecules, such as chemokines, have the potential to recruit and activate specific subsets of immune cells. 9 Among them, fractalkine (CX 3 CL1) is the only member of the CX 3 C family. It exists as a membranebound glycoprotein with 4 different domains: a chemokine domain tethered to the cell surface via a heavily glycosylated mucin-like stack, which, in turn, is attached to transmembrane and cytoplasmic domains. CX 3 CL1 exerts its biological activity by binding the chemokine domain to a high-affinity pertussis toxin-sensitive 7-transmembrane G-protein-coupled receptor known as CX 3 C receptor 1 (CX 3 CR1) expressed on monocytes/ macrophages, T cells, and natural killer cells. 10 The ligand CX 3 CL1 exists and functions in 2 forms: the membrane-anchored form, which acts as an adhesion molecule, and the soluble form, with a potent chemoattractant activity for CX 3 CR1-expressing leukocytes. [10] [11] [12] The CX 3 CL1/CX 3 CR1 axis has been implicated in the pathogenesis of cardiovascular disease. In this regard, interrupting the CX 3 CL1/CX 3 CR1 interaction in vivo was seen to limit monocytic cell recruitment to vascular lesions and to produce a highly protective effect in animal models of atherosclerosis. [13] [14] [15] In humans, the identification of a mutant form of CX 3 CR1, termed CX 3 CR1-M280, was found to be defective in mediating adhesive and chemotactic activity. 16, 17 This mutated form of CX 3 CR1 was linked to lower risk of atherosclerosis, acute coronary events, and coronary artery endothelial cell dysfunction. 16, 17 More recently, CX 3 CR1 upregulation has been detected in circulating monocytes of patients with coronary artery disease. 18 Despite intensive research, the precise molecular mechanisms by which Ang-II exerts differential leukocyte recruitment in arterial and venous endothelia remain largely unknown. Given that CX 3 CL1 is a potent chemoattractant for monocytes and T cells but not for neutrophils 10 and because TNFα is the main inducer of CX 3 CL1 expression in endothelial cells, 19 we have investigated the potential involvement of CX 3 CL1 in the arterial mononuclear cell recruitment induced by Ang-II. Accordingly, we studied the functional consequences of CX 3 CR1 genetic deletion for Ang-II-induced leukocyte-endothelial cell interactions in vivo. In vitro studies in primary cultures of human arterial and venous endothelial cells were also carried out to determine whether Ang-II promotes CX 3 CL1 expression to explore its functional role and to throw light on the underlying mechanisms involved in these responses.
Materials and Methods

In Vivo Animal Studies
Animals
Male mice of C57BL/6 background carrying targeted knockin of green fluorescent protein to disrupt the CX 3 CR1 gene have been used in numerous studies, 20 in which male CX 3 CR1 gfp/+ mice were used as heterozygote controls (CX 3 CR1 −/+ ) and homozygote CX 3 CR1 gfp/gfp animals that do not express CX 3 CR1 receptor were used as CX 3 CR1-deficient mice (CX 3 CR1 −/− ). Animal colonies were bred and maintained under specific pathogen-free conditions. The mice were fed throughout the experimental period with autoclaved balanced diet and water. Animals weighed 22 to 30 g at the time of the experiments.
The study was carried out in accordance with the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health and was approved by the Ethics Review Board of the Faculty of Medicine, University of Valencia.
Intravital Microscopy
The mouse cremaster preparation used in this study was similar to that described previously. 21 Mice were anesthetized by intraperitoneal injection with a mixture of xylazine hydrochloride (10 mg/kg) and ketamine hydrochloride (200 mg/kg), and 100 μL of vehicle or 0.1 μmol/L Ang-II was injected intrascrotally. Responses were determined 24 hours later. Animals were again anesthetized, and a polyethylene catheter was placed in the jugular vein to permit the intravenous administration of additional anesthetic (30 µL IV) every 20 minutes to maintain profound anesthesia until the end of the experiment (2 hours), and then animals were humanely euthanized by anesthetic overdose. Additional details of the technique are provided in the online-only Data Supplement.
Histology and Immunohistochemistry
Immunofluorescence studies were performed in the cremasteric microcirculation following a protocol similar to that previously described. 22 Details of the procedure are found in the online-only Data Supplement.
Human In Vitro Studies
All investigation with human samples carried out in the present study was in accordance with the principles outlined in the Declaration of Helsinki and was approved by the institutional Ethics Committee at the University Clinic Hospital of Valencia, Spain. Written informed consent was obtained from all volunteers.
Cell Culture
Human umbilical arterial endothelial cells (HUAEC) and human umbilical vein endothelial cells (HUVEC) were isolated by collagenase treatment 8 and maintained in human endothelial cell-specific medium (EBM-2) supplemented with endothelial growth media (EGM-2) and 10% FCS. Cells up to passage 1 were grown to confluence. Before every experiment, cells were incubated for 16 hours in medium containing 1% FCS.
Reverse Transcriptase Polymerase Chain Reaction
Total RNA was isolated from cultured HUAEC and HUVEC using TRIzol isolation reagent. Details are found in the online-only Data Supplement.
Flow Cytometry
After treatment, endothelial cells were detached from culture flasks using ice-cold PBS containing 0.05% NaN 3 and 0.2% BSA, followed by scraping and centrifugation. Details are provided in the onlineonly Data Supplement.
Leukocyte-Endothelial Cell Interactions Under Flow Conditions
HUAEC and HUVEC were grown to confluence and subjected to different treatments. Human mononuclear cells were obtained from buffy coats of healthy donors by Ficoll-Hypaque density gradient centrifugation. Further details are found in the online-only Data Supplement.
Immunofluorescence CX 3 CL1 expression was visualized in HUAEC and HUVEC by indirect immunofluorescence. Details are described in the online-only Data Supplement.
Western Blot
The effect of Ang-II on CX 3 CL1 expression was determined by immunoblotting. Further details are provided in the online-only Data Supplement.
Transfection of TNFα, Nox 2, Nox 4, or Nox5 siRNA
In endothelial cells, gene silencing was performed using either control or TNFα, Nox 2-, Nox 4-, or Nox 5-specific small interfering RNA (siRNA). Details are described in the online-only Data Supplement.
Experimental Protocols
The details of all the experimental protocols followed in this study are provided in the online-only Data Supplement.
Determination of CX 3 CL1 Receptor (CX 3 CR1) Expression by Flow Cytometry
The procedure for determining CX 3 CR1 expression on circulating leukocytes can be found in the online-only Data Supplement.
Materials
All materials used are listed in the online-only Data Supplement.
Statistical Analysis
Values were expressed as mean±SEM. Differences between 2 groups were determined by paired or unpaired Student t test, as appropriate. Data within multiple groups were compared using an ANOVA (1-way ANOVA), including a Newman-Keuls post hoc test for multiple comparisons. Data were considered statistically significant when P<0.05. Neither arteriolar nor venular shear rates were modified by these treatments (data not shown). Immunofluorescence analysis of the cremasteric microvasculature was performed. As illustrated in Figure 1D , stimulation with Ang-II resulted in a substantial increase in endothelial CX 3 CL1 expression within the cremasteric arterioles and postcapillary venules.
Results
Arteriolar
Effect of Losartan on Atherosclerosis Development and Cell Composition in ApoE −/− Mice on Atherogenic Diet
In an attempt to investigate the potential relevance of these findings in atherosclerosis, 6-week-old apoE −/− mice were fed with a high-fat atherogenic diet for 6 additional weeks. A group of animals were treated with an Ang-II AT 1 receptor antagonist, losartan, for the same period of time. As is illustrated in Figure  I in the online-only Data Supplement, the animals subjected to an atherogenic diet showed increased lesion formation, infiltration of macrophages and T cells, as well as enhanced CX 3 CL1 mRNA expression within the lesion. Interestingly, chronic treatment with losartan substantially decreased these responses.
Ang-II Induces CX 3 CL1 Expression in HUAEC and HUVEC
To extend these findings to human cells, we next investigated the effect of Ang-II on CX 3 CL1 expression in arterial and venous endothelial cells. Reverse transcriptase polymerase chain reaction analysis revealed that although 1-hour TNFα stimulation caused increased CX 3 CL1 mRNA expression in HUAEC and HUVEC, exposure to Ang-II for the same period of time did not ( Figure IIA To define the potential contribution of CX 3 CL1 to mononuclear leukocyte-endothelium interactions induced by Ang-II, we performed an in vitro assay using the dynamic model of the flow chamber. As observed in the in vivo studies, mononuclear leukocyte adhesion to Ang-II-stimulated HUAEC and HUVEC was markedly increased ( Figure 2E and 2F). Notably, neutralization of CX 3 CL1 activity in arterial endothelial cells resulted in a significant reduction in Ang-IIinduced mononuclear cell adhesion to HUAEC (73%) but not to HUVEC. These findings suggest that CX 3 CL1 upregulation seems to play a clear role in the arterial mononuclear cell recruitment that arises in response to Ang-II. Therefore, all the subsequent studies were performed in HUAEC.
Platelets also express CX 3 CR1 receptor and are involved in the CX 3 CL1-dependent mononuclear cell recruitment. 23, 24 Therefore, we first determined whether platelets were bound to the isolated mononuclear cells and found increased staining of the platelet marker CD41 in the leukocyte population (CD45 
TNFα Is Involved in Ang-II-Induced CX 3 CL1 Expression and Mononuclear Cell Arrest in HUAEC
The potential involvement of endogenous endothelial TNFα in Ang-II-induced CX 3 CL1 expression and mononuclear cell adhesion to HUAEC was also investigated. To suppress TNFα expression by endothelial cells, we adopted a siRNA approach. Forty-eight hours after transfection with TNFα-specific siRNA, HUAEC showed a >80% decrease in TNFα mRNA and a >74% reduction in protein compared with levels detected in control siRNA-treated cells ( Figure 3A and 3B) . In control siRNA-transfected cells, 1 µmol/L Ang-II stimulation for 24 hours produced significant increases in CX 3 CL1 expression and mononuclear cell arrest ( Figure 3C and 3D). In contrast, these responses were abrogated in TNFα-deficient HUAEC ( Figure 3C and 3D ).
Nox 5, But Not Nox 2 or Nox 4, Is Involved in Ang-II-Induced CX 3 CL1 Expression and Mononuclear Cell Arrest in HUAEC
The production of ROS and activation of redox-sensitive signaling pathways mediate many of the inflammatory responses of Ang-II. 25, 26 Because potential sources of superoxide anion in the vasculature include the activation of NADPH oxidases (Nox) and xantine oxidase, 27 we next aimed to assess whether these enzymes are involved in Ang-II-induced responses. Preincubation of endothelial cells for 1 hour with an unspecific NADPH inhibitor (apocynin) decreased Ang-II-induced CX 3 CL1 protein expression and mononuclear cell adhesion by 93.3% and 73.3%, respectively ( Figure 4A and 4B ). In contrast, pretreatment of endothelial cells with the xantine oxidase inhibitor allopurinol did not exert any activity on these parameters ( Figure 4A and 4B) .
Nox 2, Nox 4, and Nox 5 are the most abundant Nox isoforms in endothelial cells. 26 Therefore, to determine which Nox isoforms are involved in Ang-II-induced responses, we again used an siRNA approach. Significant reductions (75%- 
28-31
The activation of these different components of the MAPK family is associated with that of nuclear factor (NF)-κB. 31, 32 In addition, some of these vascular signaling pathways have been implicated in CX 3 CL1 expression. 33, 34 Thus, we examined the potential involvement of these signaling pathways in Ang-II-induced responses. Preincubation of arterial endothelial cells with an ERK1/2 or a p38MAPK inhibitor but not with a JNK inhibitor undermined the CX 3 CL1 expression induced by Ang-II stimulation by 82% and 93%, respectively ( Figure  5A ). Consequently, pretreatment of HUAEC with an NF-κB inhibitor resulted in a significant reduction in the chemokine expression induced by the Ang-II ( Figure 5A ). These inhibitory responses were accompanied by drastic decreases in the mononuclear cell-arterial endothelium interactions elicited by Ang-II ( Figure 5B ).
Ang-II, TNFα, and INFγ Synergistically Stimulate CX 3 CL1 Expression and Leukocyte Adhesion to HUAEC
It is well documented that inflammatory cytokines, such as TNFα or interferon-γ (IFNγ), can synergistically induce the surface expression of CX 3 CL1 in human endothelial cells. 19, 34, 35 Such a scenario can be envisaged in both acute and chronic inflammatory processes such as atherosclerosis, where the concomitant presence of both cytokines with Ang-II is very likely to occur. As illustrated in Figure 6A , compared with the signal detected in unstimulated cells, an increase in the mean fluorescence intensity was observed when HUAEC were stimulated independently with Ang-II, TNFα, or IFNγ for 24 hours ( Figure 6A ). As expected, we found a cooperative effect of TNFα and IFNγ on endothelial CX 3 CL1 induction ( Figure 6A ). However, although the combination of Ang-II with TNFα caused a remarkable increase in CX 3 CL1 expression compared with Ang-II alone, the combination with IFNγ did not. Indeed, when the 3 stimuli were applied together, a further enhancement of CX 3 CL1 expression was detected with respect to the fluorescence signal obtained in the presence of combinations of just 2 of the stimuli ( Figure 6A ). These results suggest a potential synergism between Ang-II and these 2 cytokines in inducing CX 3 CL1 expression. In line with these observations, the combination of TNFα, IFNγ, and Ang-II significantly increased mononuclear cell adhesion to HUAEC compared with that induced by each stimulus alone. In addition, although the contribution of CX 3 CL1 to IFNγ-induced mononuclear cell adhesion was not significant, it was found to be relevant in the mononuclear recruitment induced by the combination of IFNγ+Ang-II, IFNγ+TNFα, or IFNγ+Ang-II+TNFα, where neutralization of CX 3 CL1 activity inhibited these responses by 46% to 56% ( Figure 
Discussion
In this study, we report for the first time that CX 3 CL1 seems to be a crucial molecule in the selective arterial mononuclear cell recruitment induced by Ang-II. The first evidence to support this contention was provided by the results of our in vivo studies; although CX 3 CL1 expression was virtually absent in nonstimulated microvessels, increased expression was detected in the cremasteric arterioles and postcapillary venules of the animals intrascrotally injected with Ang-II, particularly in the arterial endothelium. Interestingly, the deficiency in fractalkine receptor (CX 3 CR1) resulted in a dramatic decrease in Ang-II-induced leukocyte adhesiveness to the arteriolar endothelium without significantly affecting leukocyte recruitment in the postcapillary venules of the same animals. In this in vivo setting, monocytes seem to be the main type of cell interacting with the Ang-II-stimulated arterioles, because CX 3 CR1 expression in mice is largely restricted to these cells 37 and a ) monocytes was reported to patrol resting vessels and rapidly extravasate in the early inflammatory response. 37 However, it has been shown that absence of CX 3 CR1 results in a significant reduction in Gr1 low blood monocyte levels, 38 which may account for the results observed in this study and the decreased macrophage infiltration in the atherosclerotic lesions found in animal models of atherosclerosis with CX 3 CR1 deficiency. 14, 15 Conversely, studies in CX 3 CL1-deficient mice or treated with neutralizing antibodies against CX 3 CL1 showed similar reductions, despite equivalent leukocyte numbers. 13, 39 Finally, we have shown that a treatment for just 6 weeks with losartan promoted substantial reductions in atherosclerosis lesion formation, CX 3 CL1 mRNA expression, and mononuclear cell infiltration in apoE −/− mice subjected to an atherogenic diet. Therefore, CX 3 CR1 + patrolling cells are likely to be recruited by Ang-II-stimulated arterioles.
Therefore, in light of these in vivo findings, we set out to translate the evidence to human cells. We show that the interaction of Ang-II with its AT 1 receptor increases CX 3 CL1 expression in human arterial and venous endothelial cells. The use of different in vitro approaches revealed that the expression of this chemokine seems to be higher in HUAEC than in HUVEC. In addition, and in accordance with our in vivo data, in vitro neutralization of CX 3 CL1 activity drastically inhibited the interactions of human mononuclear cells with the arterial endothelium (73%) but not those with the venous endothelium. At the shear conditions used in this study (0.5 dyn/cm 2 ), platelets did not significantly contribute to the CX 3 CL1-dependent leukocyte adhesion induced by Ang-II, confirming previous findings in which CX 3 CL1 alone was sufficient to promote leukocyte capture at low shear rates. 24, 39 The differential effects displayed by Ang-II in each type of endothelia suggest that CX 3 CL1 is crucial for mononuclear cell adhesion to the arterial endothelium, whereas CX 3 CL1 acts in combination with other components Published studies have reported increased CX 3 CR1 expression in circulating monocytes of patients with coronary artery disease. 18 Furthermore, a genetic polymorphism found in the gene encoding the human CX 3 CL1 receptor, CX 3 CR1-M280, was associated with a decreased risk of atherosclerosis in heterozygote individuals. 16, 17 Because Ang-II levels are elevated in many cardiovascular diseases 1,2 and human mononuclear cells express the Ang-II AT 1 receptor, the potential upregulation of CX 3 CR1 in human monocytes and lymphocytes by Ang-II was also investigated. We observed that Ang-II stimulation of these leukocyte subsets did not alter their CX 3 CR1 expression profile. Based on these findings, Ang-II-induced arterial CX 3 CL1 expression and the mononuclear cell capture associated with it would appear to be because of a direct action of the peptide on the endothelium.
As previously outlined, selective mononuclear leukocyte adhesion to Ang-II-stimulated arterioles was found to be largely mediated by TNFα in vivo, 8 and this cytokine promotes the expression of CX 3 CL1 in endothelial cells. 11, 19, 42 In an attempt to characterize the mechanisms involved in CX 3 CL1-mediated mononuclear cell adhesion to Ang-II-stimulated arterial endothelial cells, we first knocked down TNFα expression in HUAEC. TNFα deficiency in the arterial endothelium undermined Ang-II-induced CX 3 CL1 upregulation and the subsequent mononuclear leukocyte-arterial endothelium interactions. Therefore, it is tempting to speculate that Ang-II-induced CX 3 CL1 expression is the consequence of TNFα release, which may exert autocrine/paracrine effects in the arterial endothelium and likely in other CX 3 CL1-expressing vascular cells.
Several lines of evidence indicate that the endothelial cell activation that accompanies inflammation generally results in an increase in ROS production, which is largely attributed to enzymes such as Nox and xantine oxidase. 27 In our study, nonspecific NADPH inhibition blunted the responses to Ang-II, whereas xantine oxidase inhibition did not cause any significant effect. Accordingly, albeit in vascular smooth muscle cells, increased CX 3 CL1 expression was found to be oxidative stressdependent. 43, 44 However, little is known regarding the relative contribution of Nox isoforms to the endothelial inflammatory responses induced by Ang-II. Here, we show that Nox 2, Nox 4, and Nox 5 expression in human arterial endothelial cells rose after stimulation with Ang-II. Conversely, selective endothelial deletion of these isoforms revealed that only Nox 5 played a major role in Ang-II-induced increased CX 3 CL1 expression and the mononuclear cell arrest associated with it. In this regard, endothelial Nox 5 has recently been reported to be involved in the inflammatory responses induced by Ang-II, including the increased upregulation of CAMs such as vascular cell adhesion molecule-1. 30 That study also pointed to the potential interaction of Nox 5 with other Nox isoforms; activity that would probably be inhibited under Nox 5 deficiency or downregulation.
Ang-II can boost the induction of the expression of a variety of redox-sensitive factors, as well as redox-regulated genes and transcription factors. 28, 30, 31, 45 Using a pharmacological approach, we have consistently demonstrated that Ang-II-induced CX 3 CL1 arterial expression and mononuclear cell adhesiveness are regulated through ERK1/2 and p38MAPK activation and that both pathways are involved in endothelial CX 3 CL1 upregulation. 33, 34 Both ROS and MAPKs can regulate the transcription of many genes through their action on downstream targets, such as NF-κB 31, 32 Indeed, disruption of NFκB transactivation effectively blocked Ang-II-induced responses in our study, as previously observed for other CX 3 CL1-inducing cytokines. 34, 43 Taken together all these findings and although Ang-II-induced signal transduction mechanisms converge with many of TNFα, 45 it is likely that Ang-II-induced fractalkine synthesis is secondary to TNFα formation because increased CX 3 CL1 mRNA expression was detected after 4 hours of Ang-II stimulation but not at 1 hour. It has recently reported that Nox5 is constitutively expressed in endothelial cells and TNFα stimulation leads to increased Nox5 expression and subsequent ROS production. 45 Nox5-derived ROS can modulate intracellular signaling via several redox-sensitive pathways, such as ERK1/2 and p38MAPK, 45 and MAPK activity leads to activation of several transcription factors, including NF-κB. Finally, NF-κB through further regulation of genes encoding CX 3 CL1 34, 43 can cause its synthesis and expression on the endothelial cell surface, which actively participates in the mononuclear leukocyte recruitment induced by Ang-II.
Several proatherogenic cytokines, including TNFα, IFNγ, and IL-1α, cause CX 3 CL1 upregulation. 11, 19, 35 Furthermore, costimulation of IFNγ and TNFα results in a synergistic effect in inducing CX 3 CL1 expression in endothelial cells. 19, 34, 35 Inasmuch, it is likely that Ang-II and the aforementioned cytokines coexist in the atherogenic scenario, thus producing functional consequences. However, although we saw that the combination of Ang-II and TNFα caused more pronounced increases in mononuclear leukocyte-arterial endothelium adhesiveness than those detected when either stimulus was applied alone, the combination of Ang-II and IFNγ did not seem to produce any special effect. Because Ang-II-induced CX 3 CL1 expression is TNFα-dependent, a combination of both mediators (Ang-II+TNFα) is likely to produce an increase in TNFα concentrations in the inflammatory milieu. Unlike TNFα, with which CX 3 CL1 mRNA in HUAEC was observed as early as 1 hour, Ang-II and IFNγ require more time to increase chemokine mRNA expression as shown here and in previous reports. 34 In other words, although TNFα caused transcriptional activation in the induction of CX 3 CL1, posttranscriptional regulation was found to be involved in the synergism between TNFα and IFNγ, when TNFα was added to the cells after 1-hour stimulation with IFNγ. 34 These observations might explain the lack of synergism between Ang-II and IFNγ in our study. Despite these findings, the combination of Ang-II with these cytokines synergistically induced surface expression of CX 3 CL1 in human arterial endothelium, thereby increasing the adhesive properties of HUAEC for mononuclear cells. The present results extend previous findings pointing to CX 3 CL1 expression and function in atherogenesis being under the control of Ang-II and multiple cytokines.
In conclusion, this is the first report that demonstrates in vivo and in vitro that CX 3 CL1 is a key molecule in the differential adhesive properties in arterial and venous endothelia in response to Ang-II. Indeed, the interaction of membraneexpressed CX 3 CL1 on Ang-II-activated arterial endothelial cells and CXC 3 R1 on mononuclear cells seems to be responsible for a considerable proportion of the adhesion between the 2 cell types. ROS generation and the subsequent activation of redox-sensitive signaling pathways seem to mediate these responses. In light of this evidence, the development of therapeutic protocols targeting the CX 3 CL1/CX 3 CR1 axis may be beneficial in the treatment of cardiovascular diseases associated with renin-angiotensin system activation.
